Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

Running, not enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: oGHVD

In brief

A Double-Masked, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of d-MAPPS™ Ophthalmic Solution in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGHVD)

Key facts

Study ID

NCT06852768

Run by

Regenerative Ocular Immunobiologics LLC

People needed

15

Starts

2025-01-10

Expected to finish

2026-12-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Willing and able to provide written informed consent.
• Willing and able to comply with study assessments for the full duration of the study.
• Patients may be using bilateral scleral lenses and/or bilateral punctal plugs at the time of accrual.
• Minimum Oxford Schema grad of ≥ 1 in at least one eye.
• OSDI scored of ≥ 22.
• UNC DEMS score of ≥ 3.
• In good stable overall health.

You may not qualify if…

• History of Rheumatoid Arthritis, Lupus, Scleroderma.
• Ocular or periocular malignancy.
• Significant change, as judged by the principal investigator, in systemic immunosuppressive regimen within 2 weeks of study entry.
• Any history of topical tacrolimus use.
• Any change in dosage of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the last month.
• Any change in frequency of preserved anti-glaucoma medications within 2 weeks of study entry.
• Current use of topical steroids more than twice a day.
• Corneal epithelial defect > 1mm2.
• Any history of herpetic keratitis.
• Participation in another simultaneous medical research study.
• Signs of current infection, including fever and current treatment with antibiotics.
• All vaccination including COVID are prohibited during this study.
• Signs of current infection, including fever and current treatment with antibiotics.
• All vaccinations including COVID are prohibited during this study.
• Intra-ocular surgery or ocular laser surgery within 3 months.
• Women who are pregnant, breastfeeding, or plan to become pregnant while participating in the study. If of childbearing potential, unwillingness to use effective birth control while participating in the study.
• Any condition (including language barrier) that precludes patient's ability to comply with study requirements including completion of study.

Where it is running

• Beverly Hills Institute of Ophthalmology — Beverly Hills, California, United States
• Beach Eye Medical Group — Huntington Beach, California, United States
• Regenerative Ocular Immunobiologics, LLC. — Palm Harbor, Florida, United States
• Glenn Eye Center — Lexington, Kentucky, United States
• Eyewell, LLC. — Boston, Massachusetts, United States
• BostonSight — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.